<DOC>
	<DOCNO>NCT00004428</DOCNO>
	<brief_summary>OBJECTIVES : I . Evaluate safety ascend dos CPX administer adult patient mild cystic fibrosis . II . Evaluate pharmacokinetics ascend dos CPX patient population .</brief_summary>
	<brief_title>Phase I Randomized Study CPX Treatment Adult Patients With Mild Cystic Fibrosis</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize , double blind , placebo control , dose escalation study . There 7 experimental cohort , treat different oral dose CPX placebo . Within cohort , 4 patient receive single dose CPX 1 patient receives placebo . Each patient monitor 24 hour postdose . Escalation next dose level subsequent cohort begin safety data obtain previous cohort review found limit dose escalation . All patient return follow evaluation 1 week dosing .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Mild cystic fibrosis Not pregnant nursing Negative pregnancy test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2000</verification_date>
	<keyword>cardiovascular respiratory disease</keyword>
	<keyword>cystic fibrosis</keyword>
	<keyword>genetic disease dysmorphic syndrome</keyword>
	<keyword>rare disease</keyword>
</DOC>